65,437 trials
Abdominal Aortic Aneurysms
Primary: Number of Participants With Major Adverse Events (MAE) Through 30 Days — 0 participants
Spinal Cord Injury · Sleep-disordered Breathing · Spinal Cord Disease
Primary: PAP Adherence — 22.03; 18.54 nights
HIV-1 Infection
Primary: Percentage of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events (TEAEs) — 0; 0; 0; 33.3 percentage of…
Alcohol Drinking
Primary: mL Per 15 Minutes — 85.850; 80.575; 114.104 mls of alcohol consumed per 15 minutes
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Untreated Chronic Lymphocytic Leukemia
Primary: Participants With a Clinical Response — 0 Participants
Inflammatory Bowel Disease · Perianal Fistula · Crohns Disease
Primary: Objective 1: Number of CD Participants Who Have CPAF Using Various Codes in an TOH Database — 120; 120; 127; 127 Participants
Sleep Apnea Syndromes · Sleep Disorder · Sleep
Primary: Peripheral Arterial Tone Apnea-hypopnea Index (PAHI) — 13.3 events per hour
Sudden Cardiac Death · Heart Failure
Primary: Proportion of Patients Saying "Yes" to ICD — 123; 60; 87; 41 Participants
Ovarian Cancer
Primary: Inter-rater Reliability of Positron Emission Tomography (PET) Maximum Standardized Uptake Value (SUVmax) - Individual Intra-class Correlation Coefficients by Location…
Recurrent Breast Cancer · Metastatic Breast Cancer
Primary: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] — 15 mg
Proliferative Diabetic Retinopathy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants
Advanced Non-Clear Cell Kidney Cancer
Primary: Best Overall Response Rate — 33 percentage of participants
Biliary Strictures
Primary: Safe Stent Removal — 33 Participants
Prostate Cancer
Primary: Number of Participants With Clinically Significant Cancer — 38; 31 Participants
Atopic Dermatitis
Primary: Baseline of Disease Characteristics Before Treatment With SUN13834 or Placebo in Adult Participants With Atopic Dermatitis — 12.59; 12.45; 6.01; 3.0 score on a scale